Interestingly, higher expression of these macrophage markers was associated with worse outcomes of ER+, HER2+, TNBC, and all subtypes, respectively (Fig. S5C, D), suggesting that these four subsets might be indicators of worse prognosis in their respective breast cancer patients. This evidence concerns the gene ESR1 and breast cancer.